Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 20/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627326 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL29798973 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL118150 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4628832 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4628249 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL4627368 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL4628840 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL4629325 | 0.95 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL4628865 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4629383 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1ADRB3CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093866-A1 | Pharmaceutical Formulations | MONTEITH MICHAEL JOHN | 2010-04-15 | — | — | US | claimed |
| US-20090123391-A1 | Novel Formulations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | US | claimed |
| US-7442839-B2 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-28 | — | — | US | claimed |
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | claimed |
| US-20060239932-A1 | Pharmaceutical formulations comprising magnesium stearate | GLAXO GROUP LIMITED (GB) | 2006-10-26 | — | — | US | claimed |
| US-20060233716-A1 | Pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| US-20060210485-A1 | Pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | US | claimed |
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | claimed |
| EP-1646370-A1 | PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | claimed |
| EP-1643973-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING MAGNESIUM STEARATE | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | claimed |
| EP-1643974-A1 | INHALABLE PHARMACEUTICAL FORMULATIONS COMPRISING A SUGAR ESTER | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | claimed |
| WO-2006008173-A2 | PHARMACEUTICAL FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| EP-1556342-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | claimed |
| WO-2005004846-A1 | PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
| WO-2005004852-A1 | PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
| WO-2005004845-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING MAGNESIUM STEARATE | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
| WO-2004037773-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | claimed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004037773-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123391-A1 | Novel Formulations | PFN1, CCL11, MFAP1 | ADRB2 61/4885ADRB1 79/4885ADRB3 25/4885 |
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | PHOSPHO1, PNMT, NAPEPLD | ADRB2 83/4885ADRB1 176/4885ADRB3 155/4885 |
| US-20060239932-A1 | Pharmaceutical formulations comprising magnesium stearate | SLCO2A1, SLCO1B1, SLCO2B1 | ADRB2 3370/4885ADRB1 2804/4885ADRB3 2042/4885 |
| US-20060210485-A1 | Pharmaceutical formulations | SLCO2A1, SI, SLCO2B1 | ADRB2 2390/4885ADRB1 1809/4885ADRB3 1156/4885 |
| US-20100093866-A1 | Pharmaceutical Formulations | SUCNR1, SI, SLC5A6 | ADRB2 3964/4885ADRB1 3962/4885ADRB3 3623/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | ADRB2 2326/4885ADRB1 2244/4885ADRB3 668/4885 |
| US-20060233716-A1 | Pharmaceutical formulations | SLCO2A1, SLCO1B3, SLCO1B1 | ADRB2 3286/4885ADRB1 2499/4885ADRB3 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.